ArticleProbiotics and antimicrobial proteins2026
Immunomodulatory Effects of Bifidobacterium bifidum BGN4 in Cyclophosphamide-induced Immunosuppressed Mice via Activation of NK Cells and Macrophages.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system is a highly coordinated network that defends the host against pathogens and maintains physiological homeostasis. Probiotics have emerged as promising immunoregulatory agents; however, the mechanisms by which they modulate innate and adaptive immune responses remain incompletely understood. In this study, we investigated the immunomodulatory potential of Bifidobacterium bifidum BGN4 using in vitro assays and a cyclophosphamide (CP)-induced immunosuppressed mouse model. In vitro, B. bifidum BGN4 treatment markedly enhanced natural killer (NK) cell cytotoxicity against YAC-1 lymphoma target cells and activated macrophages, as evidenced by elevated nitric oxide production, increased secretion of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), and upregulated expression of phagocytosis-related genes (Marco, Msr1, and Cd14). These effects were accompanied by activation of MAPK and NF-κB signaling pathways in macrophages. In vivo, oral administration of B. bifidum BGN4 significantly mitigated CP-induced reductions in body weight, spleen and thymus indices, and leukocyte counts. Moreover, B. bifidum BGN4 enhanced splenocyte proliferation under both basal and mitogen-stimulated conditions and improved NK cell cytotoxic activity in immunosuppressed mice. Collectively, these findings demonstrate that B. bifidum BGN4 promotes both innate and adaptive immune activation, effectively counteracting CP-induced immunosuppression. This probiotic strain represents a promising functional food ingredient for immune enhancement and recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.